Evidence map›Paper›PMID 37833603›Full record

ArticleDoklady. Biochemistry and biophysics2023

Comparative Pharmacoeconomic Effectiveness of Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis.

T V Dubinina, I Z Gaidukova, N A Sableva, K V Sapozhnikov, V D Sokolova, D G Tolkacheva

Erratum issuedOpen access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

T V DubininaNasonova Research Institute of Rheumatology, Moscow, Russia. tatiana-dubinina@mail.ru.
I Z GaidukovaMechnikov North-Western State Medical University, St. Petersburg, Russia.
N A SablevaRussian Presidential Academy of National Economy and Public Administration, Moscow, Russia.
K V SapozhnikovRussian Presidential Academy of National Economy and Public Administration, Moscow, Russia.
V D SokolovaRussian Presidential Academy of National Economy and Public Administration, Moscow, Russia.
D G TolkachevaRussian Presidential Academy of National Economy and Public Administration, Moscow, Russia.
The Russian Presidential Academy of National Economy and Public Administration · RUAssociation of Rheumatologists of Russia · RUNorth-Western State Medical University named after I.I. Mechnikov · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to compare the clinical efficacy and cost-effectiveness of IL-17 inhibitors (SEC, IXE, NTK) in the treatment of adult patients with ankylosing spondylitis (AS) in the healthcare system of the Russian Federation. Materials and methods. The study is a sub-analysis of a previously published systematic review and network meta-analysis of the comparative efficacy of biologics in adult patients with AS in the Russian Federation. NNT values were calculated for BASDAI 50 and ASAS 20/40 after 16 weeks of therapy for all studied drugs. CpR was estimated for each biologic after 16 weeks and one year of therapy. Additionally, we carried out an assessment of the financial burden of the most cost-effective strategies for the treatment of AS. The use of NTK is characterized by an average of no more than three patients needed to treat to achieve one ASAS 20/40 or BASDAI 50 response, while on IXE and SEC no more than 4-5 patients need to be treated, depending on the estimated effectiveness criterion. According to CpR estimate, NTK is the most cost-effective IL-17 inhibitor for the treatment of AS, both after 16 weeks and after one year of therapy. The obtained results make it possible to compare the effectiveness of IL-17 inhibitors from a clinical and economic points of view and can be used both in decision making on treatment strategies for individual patients and at the population level when deciding on the reimbursement of drugs.

Indexed as

Spondylitis, AnkylosingAdultEconomics, PharmaceuticalHumansInterleukin-17Severity of Illness IndexTreatment OutcomeTumor Necrosis Factor-alphaInterleukin-17Tumor Necrosis Factor-alphaankylosing spondylitisbiologicsgenetically engineered biological agentsinterleukin 17 inhibitornetwork meta-analysis

Identifiers

PMID37833603
PMCPMC10739179
OpenAlexW4387633679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.